CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Lenalidomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01246076
NCT01246076Phase 2Completed
CompareCT.gov

Phase II Trial of High Dose Lenalidomide in Patients With Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Washington University School of Medicine·interventional·Posted Nov 23, 2010·Updated Jan 5, 2016

In Brief

A Phase 2 clinical trial evaluating Lenalidomide for Myelodysplastic Syndromes. Completed, enrolled 24 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine the proportion of confirmed responses (complete response, partial response, and hematologic improvement as defined by revised IWG criteria during the 12 months of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndromes
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 23, 2010
Enrollment StartJun 1, 2011
Primary CompletionMay 1, 2014
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 15.6 years ago

Interventions

Lenalidomidedrug